AIFA, Withdraws Batch of An Anti -Bitic Specialty Drug Azithromycin Zentiva

The Italian Medicines Agency (AIFA), Has Orthoded The Withdrawal of the Batch n. 2540116 SCAD. 12-2017 of the Medicinal Specialty Azitromycin Zen*3CPR RIV500MG – AIC 038667022 from the company Zentiva Italia srl. The measure, points out Giovanni D’Agata, president of the "Sportello deiRights," was necessary following the Czech Republic's Rapid Alert and the company's communication regarding a potential smear event at the secondary packaging level of the aforementioned medicine.

Azithromycin Zentiva is used for thirty azithromycin is an antibiotic belonging to the macrolide class and indicated in the thirty of bacterial infections sustained by pathogens sensitive to the active ingredient. It is useful in respiratory tract infections (bronchitis, pneumonia, sinusitis, tonsillitis, and pharyngitis); Genital Infections Such as Chlamydia and Gonorrhea; Prostatitis and urethritis; Soft Ulcer (Sustained by Haemophilus Ducreyi); Mycoplasma Hominis Infections; Dedontostomatologic Infeszions; and skin and soft tissue infections.

It is also effective in the Treatment of Legionnaire's Syndrome; Crohn's Disease; Protozoal Infections Caused by Toxoplasma; Mild Acute Bacterial Sinusitis; Acne inflammotory; Bacterial Conjunctivitis; Traveler's Diarrhea, As Well As Erandication of Helicobacter Pylori (in Combination with Other Drugs). The Batch in Question May Not Be used, and the Sanofi Group Company Zentiva Must Ensure Its Withondwal Within 48 Hours of Receiving The Order.